Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LAP3 | P28838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7570633 | 0.98 | KDM4C (0.41) | KDM4CKDM4APHF8KDM2AFDPS | |
| SCHEMBL7947910 | 0.98 | KDM4C (0.41) | KDM4CKDM4APHF8KDM2AFDPS | |
| SCHEMBL2302042 | 0.98 | KDM4C (0.41) | KDM4CKDM4APHF8KDM2AFDPS | |
| SCHEMBL7950976 | 0.98 | KDM4C (0.41) | KDM4CKDM4APHF8KDM2AFDPS | |
| SCHEMBL4943737 | 0.94 | CA1 (0.37) | FDPSCA1ALDH1A1TDP1LMNA | |
| SCHEMBL11516995 | 0.85 | CA1 (0.44) | FDPSCA1ALDH1A1TDP1LMNA | |
| SCHEMBL4575366 | 0.80 | KDM4C (0.47) | KDM4CKDM4APHF8KDM2ACA1 | |
| SCHEMBL8989558 | 0.80 | ENPP2 (0.34) | LAP3 | |
| SCHEMBL10040358 | 0.80 | ALDH1A1 (0.35) | FDPSALDH1A1TDP1LMNABLM | |
| SCHEMBL959452 | 0.79 | LMNA (0.40) | KDM4CKDM4APHF8KDM2AFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400793-A1 | COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF | MOMENTIVE PERFORMANCE MATERIALS INC. | 2024-12-05 | — | — | US | claimed |
| EP-4396271-A1 | COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF | Momentive Performance Materials Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| WO-2023034354-A1 | COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2023-03-09 | — | — | WO | claimed |
| EP-0113561-A2 | Prostaglandin intermediates, their synthesis and their conversion to prostaglandins | THE UPJOHN COMPANY (US) | 1984-07-18 | — | — | EP | claimed |
| US-4176122-A | Process for the preparation of bicyclic enone compounds | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK (HU) | 1979-11-27 | — | — | US | claimed |
| US-3992439-A | ESTERIFICATION, ACYLATION, HYDROGENATION, OXIDATION, HYDROLYZING | PFIZER INC. (US) | 1976-11-16 | — | — | US | claimed |
| JP-63216866-A | — | — | None | — | — | JP | disclosed |
| US-20240400793-A1 | COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF | MOMENTIVE PERFORMANCE MATERIALS INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2024190780-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR KIDNEY DISEASES CONTAINING TRICYCLIC COMPOUND | 小野薬品工業株式会社 | 2024-09-19 | — | — | WO | disclosed |
| WO-2024190777-A1 | TRICYCLIC COMPOUND | 小野薬品工業株式会社 | 2024-09-19 | — | — | WO | disclosed |
| US-20240287105-A1 | TREPROSTINIL ANALOGS AND RELATED METHODS OF MAKING AND USING | UNITED THERAPEUTICS CORPORATION (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4396271-A1 | COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF | Momentive Performance Materials Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023085135-A1 | COMPOUND, COMPOSITION, METHOD, AND PRODUCTION METHOD | エルデシエロ プライベート リミテッド | 2023-05-19 | — | — | WO | disclosed |
| US-3991080-A | Prostaglandin intermediates | HOFFMANN-LA ROCHE INC. (US) | 1976-11-09 | — | — | US | disclosed |
| US-3975406-A | Hexahydro-5-oxy-2-loweralkoxy-2H-cyclopenta[b]-furan-4-carbonitrile intermediates for prostaglandins | MAYER HANS JOHANN | 1976-08-17 | — | — | US | disclosed |
| US-3974185-A | Hexahydro-cyclopentano[b]furans having a 2-C.tbd.C containing substituent in the 4-position | HOFFMANN-LA ROCHE INC. (US) | 1976-08-10 | — | — | US | disclosed |
| US-3970674-A | Certain hexahydro-2-loweralkoxy-5-oxycyclopenta [b] furans containing an olefinic substituent in the 4-position | HOFFMANN-LA ROCHE INC. (US) | 1976-07-20 | — | — | US | disclosed |
| US-3953466-A | TETRAZOYL DERIVATIVES OF PROSTAGLANDINS | PFIZER INC. (US) | 1976-04-27 | — | — | US | disclosed |
| US-3953470-A | Substituted prostaglandin derivatives | SYNTEX (U.S.A.) INC. (US) | 1976-04-27 | — | — | US | disclosed |
| US-3935254-A | 5C-PROSTEN-13-YNOIC ACIDS | CARLO ERBA S.P.A. (IT) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287105-A1 | TREPROSTINIL ANALOGS AND RELATED METHODS OF MAKING AND USING | TYMP, TTPA, PTGIS | KDM4C 3962/4885KDM4A 3262/4885PHF8 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.